INTRODUCTION
C ongenital hypothyroidism (CH) is a clinical syndrome caused by thyroid hormone (TH) deficiency, resulting in reduction of metabolic processes and impaired neurodevelopment. The disorder is classified as primary when the origin of the defect is in the gland itself, or secondary, when the hypothalamic-pituitary axis is affected (1) (2) (3) (4) (5) .
Thyroid organogenesis and hormonogenesis and the structuring of the hypothalamic-pituitary-thyroid axis are essential early steps of embryonic life (3, 4, 6) . As the amount of TH that crosses the placenta is not sufficient to meet the needs of the fetus, fetal synthesis and secretion are important during the course of the gestation. Any interference that results in inadequate production of fetal TH represents a severe obstacle to the development of the synapses and neuronal myelination, which is clinically expressed by mental retardation and learning difficulties when the disorder is not diagnosed early and properly treated (4) .
Based on newborn screening programs, the prevalence of primary CH is approximately 1:3,000 to 1:4,000. Some studies suggest an ethnic variation, with a higher prevalence among Hispanics and Native Americans (1:2,000) and a lower prevalence among Blacks (1:10,000), besides preponderance of female over the male gender (2:1) (3, 5, 7, 8) . The main causes of the disorder are: thyroid agenesis; ectopia due to a failure in embryonic migration of the gland; dyshormonogenesis caused by an inborn error of one of the many steps of thyroxin synthesis; and, finally, suppression of the fetal thyroid gland by medication used by the mother (5, 8) .
The greatest challenge to control CH is neonatal detection by screening programs. The first programs of this kind were developed in Quebec (Canada) and Pittsburgh (USA) in 1974, using radioimmunoassay to measure TH in capillary blood samples obtained by heel puncture (3, 9) . In Brazil, the Newborn Screening Program started in 1976 with a project to detect phenylketonuria (PKU), coordinated by Prof. Dr. Benjamin J. Schmidt and carried out at the São Paulo Association of Parents and Friends of the Mentally Handicapped (10 According to the program protocol, blood for the neonatal screening test is ideally collected on the 5 th day of life, in order to ensure early diagnosis and onset of treatment. Once detected, the affected child is referred to a trained physician for follow-up. In Minas Gerais, this screening program was set up in 1993, and until 2008 a total of 3,574,476 children had been screened (14) .
The objective of the present study was to determine the incidence of CH in Uberaba, a medium-sized city of Minas Gerais, and to outline the screening, treatment and etiology of CH cases detected from 2001 to 2010.
MATERIAL AND METHODS

Study protocol
This is a descriptive, retrospective study, performed by reviewing patient records from a public reference outpatient unit for the treatment and follow-up of children with CH diagnosed by the State Newborn Screening Program. The study was approved by the Ethics Committee of the institution.
Neonatal screening has been systematically performed in all newborns in public healthcare facilities, and was analyzed since 2001. The healthcare units are directed to collect blood samples between the 3 rd and 5 th day of life by heel puncture and impregnation of filter paper. The material is then sent to a reference laboratory, where it is processed and TSH levels are determined. Whenever TSH concentration is higher than 25 mIU/L, parents are officially referred to the pediatric endocrinology outpatient clinic of the Hospital de Clínicas of the Federal University of Minas Gerais in Belo Horizonte, where the patient goes to a medical appointment and venous blood samples are drawn for TSH, free T4, anti-thyroperoxidase antibody, and thyroglobulin measurements.
Once CH is confirmed, i.e,. by serum TSH concentrations higher than 10 mIU/L and low free T4 (FT4), treatment is started with levothyroxine, 10-12 µg/kg/ day. The child is referred to a local physician, trained to provide proper care. Borderline TSH values in the screening test (10-25 mIU/L) indicate the need to repeat blood collection on filter paper and, if confirmed (TSH > 10 mIU/L), serum measurement and medical evaluation are also required (Figure 1 ).
Incidence coefficient = number of tests performed during the year in the city x 1000 number of live-born babies screened during the year in the city Clinical and laboratory data and the information obtained by the protocol (baby's age upon the first medical appointment, gender, clinical signs, and symptoms suggestive of CH, age at screening, value of the first serum TSH and FT4 measurements, age at the beginning of treatment and etiology of the CH) were analyzed.
Statistics
All observations were recorded in a database, using Excel 7.0 (Microsoft ® ) and GraphPad 5.0 (Graph Pad Prism ® ). Descriptive analysis based on absolute frequencies and percentages was used for the categorical variables, and measures of centrality (mean and median) and dispersion (standard deviation, coefficient of variation, minimum and maximum) were used for numerical variables. Data are presented in tables.
To calculate coverage, the following formula was used: Thereafter, the child is followed up by means of periodic medical examinations and L-thyroxine doses are adjusted according to clinical progress and periodic TSH and FT4 measurements.
After reaching three years of age, children have their medication suspended to determine CH etiology, and they undergo the following exams: thyroid scintigraphy with 123 I, ultrasound, and perchlorate test, besides antithyroperoxidase antibodies and thyroglobulin measurements.
In the studied population, TSH analysis on filter paper was performed using ELISA (enzyme-linked immunosorbent assay; reference value < 10 mIU/L), and serum TSH and FT4, anti-thyroperoxidase antibodies and thyroglobulin measurements were carried out by chemoluminescence (reference values: 0.3 to 5.0 µIU/ mL; 0.75 to 1.8 ng/dL; and < 15 IU/mL and < 30 ng/mL, respectively). The formula used to calculate the incidence coefficient per year was: Taking into account that the incidence of a disease is defined as the number of new cases that occur within a certain period of time in a population exposed to the risk of getting sick (15), we considered for the incidence calculation of each time period the number of confirmed cases screened by means of the newborn test, and the total number of newborn tests performed by the public healthare system from 2001 to 2010.
RESULTS
From 2001 through 2010, a total of 36,666 babies were born in Uberaba/MG, and 32,278 of them underwent the newborn screening test provided by the public healthcare system. Thus, 88% of the babies were screened for CH, and 16 cases were detected, indicating a CH incidence of 1: 2,017 screened newborns during this period (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) .
The percent coverage of the screening test varied from 84% to 92% and CH incidence coefficient varied from 0.00 to 1.25 cases/1,000 live-born children/year.
Of the 16 babies diagnosed with CH, 11 (68.8%) were female, representing a Female/Male ratio of 2.2:1.
Gestations of most of the babies with CH (n = 15; 93.8%) were normal; in one case, pre-eclampsia and gestational diabetes occurred. Half of the deliveries were normal and at term; one was normal but post-term (42 weeks), five babies were delivered by cesarean section, and two by pre-term cesarean section (34 and 36 weeks). Eight babies (50%) presented prolonged neonatal jaundice. One baby, small for gestational age at birth, had trisomy 21. In seven babies (43.8%), the screening test was positive, but signs did not suggest hypothyroidism. In the baby with trisomy 21, the characteristics of the syndrome were predominant. The other eight babies (50%) showed manifest hypothyroidism, with pale, dry, and rough skin or cutis marmorata, macroglossia, open anterior and posterior fontanels, umbilical hernia, and infiltrated appearance.
The newborn screening test was performed on the 5 th day of life in five of the babies diagnosed with CH, and between the 5 th and 10 th day in eight babies (mean of 7 ± 2 days). Three babies had their tests delayed (performed at 17, 20, and 30 days of life, respectively) due to intercurrences at birth.
Once the diagnosis was confirmed, therapy was started between day 14 and 59 after birth (median: 32 days; Table 1 ). Excluding the cases of late blood collection and/or recall, mean time of treatment onset was at 24.2 ± 10.2 days (14 to 48 days).
Of the 16 babies diagnosed with CH, 6 (37.5%) presented TSH < 25 mIU/L upon the first screening test, so a second blood sample was collected on filter paper, which delayed the diagnosis.
The babies' first medical visit occurred at 14 to 59 days of age (median: 32 days), when they presented the anthropometric characteristics listed in table 1.
TSH concentrations obtained in the newborn screening test, TSH and free T4 measurements performed later on, and anti-thyroperoxidase and thyroglobulin values are presented in table 2. Anti-thyroid antibodies at low concentrations do not support the existence of intrauterine autoimmune thyroiditis. There was one case with a rather low thyroglobulin level, and CH etiology in this patient is still being investigated (ultrasound showed normal topic thyroid).
An etiologic investigation was carried out in 15 children, between 3 and 4 years of age; one patient moved away from the State before the etiologic investigation was carried out. Cervical ultrasound (n = 15) showed a topic thyroid in 12 cases (80%), thyroid ectopia in one case (6.7%), and in two cases the gland was not visualized. Among the topic thyroids, (Table 3) . 
Congenital hypothyroidism: incidence and etiology
Of the children investigated thoroughly, only one case had transient hypothyroidism, so the medication was discontinued. This child was nevertheless followed up for other 2 years and, as he remained euthyroid, he was discharged from the program. Ten of the remaining children were diagnosed with permanent hypothyroidism and resumed the treatment with sodium levothyroxine. Currently, four children are waiting for a complementation of their etiologic investigation (scintigraphy and perchlorate test) while under treatment.
Neuropsychomotor development has been considered adequate for age in 12 children, except for one who presented neonatal seizures and the patient with trisomy 21. Six children are already at school age and six are at preschool age.
DISCUSSION
Access to the newborn screening test is still highly variable in Brazil, ranging from virtually 100% in the southern states to less than 60% in the northern states of the country, where geographic, political, economic, social, cultural, and educational barriers still persist (16) .
In the State of Minas Gerais, the coverage of the newborn screening program is 94.6% (17) and comprises almost 100% of the 853 cities of the state. In Uberaba, this coverage has been maintained over the years at around 88%, and we believe that the remaining babies are screened by the private healthcare system, since the socioeconomic conditions of part of the population allows them to afford private healthcare. This assumption is corroborated by 2003 data showing that almost one fourth of the Brazilian population (24.6%) was covered by private health insurance plans (18) . This overall coverage rate is similar to the States of Paraná and Santa Catarina, which in 2007 presented an 88% and 88.5% coverage, respectively (19) , and higher than in states of Pernambuco and Piauí, where in 2007 only 51% and 64% of the live-born babies were screened, respectively (20) , and Sergipe, where in 2005 the coverage was 76.3% (21) .
The incidence of CH in Uberaba is higher (1:2,017) than the reported by most of the newborn screening programs in Brazil. This city is situated in a well-developed region of the State of Minas Gerais that has been considered iodine-deficient in the past. However, there is no recent data on the regional iodine status (22 (24) .
Ideally, the age for collecting the first blood sample for TSH screening is between the 3 rd and the 5 th day of life, when the postnatal peak of physiological TSH elevation has already decreased (25) (26) (27) . In Uberaba, the mean age at the first blood collection of the diagnosed patients was 7 days, except for the three cases with late blood collection due to various reasons. This value is similar to the newborn screening program of the city of Ribeirão Preto, state of São Paulo (8 days) (12) , but higher than the limits established as ideal in the Administrative Rule no. 822 (13) of the Brazilian Ministry of Health (2 to 7 days of life). Compared with other Brazilian states, the mean of 7 days is higher than the one found in the states of Paraná (3 days) and Santa Catarina (5 days), but lower than in Rio Grande do Sul (11 days) (19) and in Paraíba (29.8 days) (28) . In a study published in 2006 on CH screening in Scotland (29), the median age at blood collection for the test was 6 days, and 93.8% of the samples were collected before eight days of life.
Treatment was started on average at 24.6 days of life and, in the last 4 years, it was observed that, even if the screening test was not carried out exactly on the 5 th day, but between the 5 th and the 10 th day, treatment was started before 20 days of age. This observation proves how fast samples are sent to the reference laboratory, results are provided, and the children officially called in for medical examination, confirmation of the diagnosis, and onset of treatment. In a further effort to start treatment as early as possible, ideally by the second week of life, the Newborn Screening Program of the State of Minas Gerais has called in children with TSH test results higher than 20 mIU/L (rather than 25) for a medical examination since 2007 (30) . In the long run, this intervention will certainly show an impact on achieving the desired results.
Comparing the data of the present study with those of other Brazilian newborn screening programs, we observed a similarity in treatment onset with the program performed at the Ribeirão Preto School of Medicine University Hospital, equal to 25.9 ± 14.2 days (12) (19) . In the Scottish study (29) , the median age at treatment start was 11 days, but 12% of the evaluated children started treatment at over 16 days of life, which was considered late.
In order to be able to start treatment as early as possible, campaigns directed to healthcare professionals have been conducted in Uberaba, so that they would instruct parents regarding the importance of early tes ting (up to the 5 th day of life), and alert the basic healthcare unit professionals about the importance of collecting blood samples properly, and quickly sending them to the reference laboratory.
So far, the analysis of CH etiology confirmed six cases of thyroid dysgenesis and four cases of dyshormonogenesis. Four cases are still under investigation (probable dysgenesis in one case and dyshormono genesis in three). Compared with the literature, where thyroid dysgenesis is predominant (9, (31) (32) (33) (34) , in the CH patients of Uberaba, dyshormonogenesis was observed to have a higher frequency. One case of iodine organification defect and three cases with a normal perchlorate test were also found. In three children with a topic thyroid on ultrasound, scintigraphy and perchlorate test are still to be performed, and molecular studies will be necessary in the future for a better etiologic definition. We raised the possibility of parental consanguinity (35) as the factor responsible for this finding, but information obtained from the parents did not confirm this hypothesis. The results found in Uberaba are consistent with a study carried out on 243 patients with CH from the Newborn Screening Program of the State of Minas Gerais from 1996 to 2003, which also observed a higher frequency of hormone synthesis defects (52%) than thyroid dysgenesis (47%) (36) .
CH is one of the most common causes of preventable mental retardation, and its natural course can be dramatically modified depending on how early it is diag nosed and how quickly proper treatment is started. Thus, every effort should be made to carry out newborn screening programs, in order to ensure early diagnosis and treatment. To reach this goal, it is important to set time patterns for each step of the screening process, because delays in one or more steps will lead to unacceptable delays in the treatment of the affected children. The Newborn Screening Program of the State of Minas Gerais is actively attempting, together with the municipal health offices, to overcome the difficulties and, consequently, reach the desired goals. Specifically in Uberaba, it is still necessary to optimize the extent of program coverage, and to reduce the age at sample collection. However, promising results are already being obtained, offering a better perspective to the patients.
